Glaukos (NYSE:GKOS) Given New $202.00 Price Target at BTIG Research

Glaukos (NYSE:GKOS) had its price target lifted by analysts at BTIG Research from $193.00 to $202.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research’s price objective indicates a potential upside of 6.47% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Truist Financial lifted their target price on shares of Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Citigroup boosted their target price on shares of Glaukos from $175.00 to $188.00 and gave the company a “buy” rating in a report on Thursday, July 30th. HC Wainwright upped their price target on shares of Glaukos from $168.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $178.08.

Glaukos Price Performance

Glaukos stock opened at $189.72 on Thursday. The stock’s 50 day moving average is $154.98 and its 200 day moving average is $130.78. Glaukos has a one year low of $73.16 and a one year high of $190.06. The firm has a market cap of $11.19 billion, a P/E ratio of -58.38 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The business had revenue of $185.61 million during the quarter, compared to the consensus estimate of $150.93 million. During the same quarter in the prior year, the firm posted ($0.24) EPS. The company’s revenue for the quarter was up 49.6% compared to the same quarter last year. As a group, research analysts expect that Glaukos will post -0.35 EPS for the current year.

Insider Activity at Glaukos

In related news, CFO Alex R. Thurman sold 20,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares of the company’s stock, valued at $7,908,787.78. This represents a 31.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 60,000 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the transaction, the chief operating officer directly owned 72,588 shares in the company, valued at approximately $13,046,967.12. This represents a 45.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 110,525 shares of company stock worth $19,125,006 in the last quarter. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Wealth Alliance LLC boosted its holdings in Glaukos by 4.5% in the first quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock worth $247,000 after acquiring an additional 98 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Glaukos by 9.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 122 shares in the last quarter. Larson Financial Group LLC grew its position in Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares during the period. CWM LLC increased its stake in Glaukos by 25.2% during the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 143 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in Glaukos by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock worth $947,000 after buying an additional 144 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks Research raised multiple long-term EPS forecasts. Estimates increased for FY2027 EPS to $0.45 from $0.38, FY2028 EPS to $1.70 from $1.56, Q4 2027 EPS to $0.33 from $0.30, Q1 2028 EPS to $0.18 from $0.16, and Q2 2028 EPS to $0.37 from $0.32. The revisions suggest stronger expected profitability as Glaukos scales its business. Zacks Research article
• Positive Sentiment: Growth catalysts remain intact. Zacks highlighted Glaukos’ iDose TR and Epioxa products, margin-expansion potential, and broad development pipeline as reasons to retain the stock. These factors support the long-term growth narrative behind GKOS.
• Neutral Sentiment: Management will participate in the Wells Fargo Healthcare Conference on September 9, 2026. The event could provide updates on product launches, clinical programs, and financial goals, although no new operating information was announced. Glaukos Wells Fargo Healthcare Conference announcement
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q2 2027 EPS forecast to $0.06 from $0.07, indicating some modest pressure in the intermediate outlook. However, the cut was outweighed by increases to most other quarterly and annual forecasts.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.